Transcriptomics

Dataset Information

0

Mechanisms of response and tolerance to active RAS inhibition in KRAS-mutant NSCLC


ABSTRACT: Resistance to inactive state-selective RASG12C inhibitors frequently entails accumulation of RASGTP, rendering effective inhibition of active RAS potentially desirable. Here, we evaluated the anti-tumor activity of the RAS(ON) multi-selective tri-complex inhibitor RMC-7977 and dissected mechanisms of response and tolerance in KRASG12C-mutant NSCLC. Broad-spectrum, reversible RASGTP inhibition with or without concurrent covalent targeting of active RASG12C yielded superior and differentiated antitumor activity across diverse co-mutational KRASG12C-mutant NSCLC mouse models of primary or acquired RASG12C(ON) or (OFF) inhibitor resistance. Interrogation of time-resolved single cell transcriptional responses established an in vivo atlas of multi-modal acute and chronic RAS pathway inhibition in the NSCLC ecosystem and uncovered a regenerative mucinous transcriptional program that supports long-term tumor cell persistence. In patients with advanced KRASG12C-mutant NSCLC, the presence of mucinous histological features portended poor response to sotorasib or adagrasib. Our results have potential implications for personalized medicine and the development of rational RAS inhibitor-anchored therapeutic strategies.

ORGANISM(S): Mus musculus

PROVIDER: GSE270541 | GEO | 2024/06/27

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-08-01 | GSE179212 | GEO
2024-12-08 | GSE283634 | GEO
2024-11-11 | GSE247512 | GEO
2024-06-17 | GSE269313 | GEO
2024-06-17 | GSE269985 | GEO
2023-05-12 | PXD039726 | JPOST Repository
2024-11-01 | GSE246804 | GEO
2021-07-29 | GSE180964 | GEO
2019-05-03 | GSE130616 | GEO
2021-04-28 | PXD023932 | Pride